Qelbree viloxazine adhd treatment fda approval?

Short answer: Yes. Qelbree (viloxazine) extended-release was approved by the FDA in 2021 for ADHD in pediatric patients aged 6 to 17. As of the most recent widely available information, there is no FDA approval for ADHD in adults.

Notes:
- Qelbree is a non-stimulant ADHD medication (a norepinephrine reuptake inhibitor).
- Dosing and safety info are in the FDA label; discuss with a clinician for individual planning.
- For the very latest status (in case there have been updates), I can look up the current FDA labeling or company announcements. Would you like me to check that now?